Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

LEASES (Tables)

6 Months Ended

Jun. 30, 2022

The components of our operating lease expense were as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Fixed operating lease expense	$	1,340	$	1,340	$	2,680	$	2,680
Variable operating lease expense		125		163		391		392
Total operating lease expense	$	1,465	$	1,503	$	3,071	$	3,072

Supplemental information related to our operating lease were as follow (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Cash payments included in the measurement of operating lease liabilities	$	2,630	$	2,529	$	5,226	$	5,025

Supplemental information related to our operating sublease was as follow (in thousands):

The following table presents the future lease payments of our operating lease liabilities as of June 30, 2022 (in thousands):


		Operating Lease		Sublease Receipts		Net
Remainder of 2022	$	5,260		(2,365)		2,895
2023		877		(394)		483
Total minimum payments required	$	6,137	$	(2,759)	$	3,378